Ligand Provides Highlights from Today’s Analyst Day Event
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Ligand Pharma (LGND) Provides Updates at Analyst Day; Roth Capital Raises Price Target to $144
November 19, 2015 7:13 AM ESTRoth Capital reiterated a Buy rating on Ligand Pharma (NASDAQ: LGND), and raised the price target to $144.00 (from $138.00), following the company's analyst day. Ligand provided financial and clinical updates, highlighting the company's continued successful "shots on goal" approach, the continued growth of its... More
Ligand Pharma (LGND) Reviews Recent Progress at Analyst Day Event
November 18, 2015 4:05 PM ESTAt an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs. Management also discussed the Captisol, LTP and SUREtechnology (owned by Selexis) formulation and delivery technologies as well as its financial outlook through... More
